Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 186

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects

Open access
Levin, Maxim, Udi, Yael, Solomonov, Inna, Sagi, Irit·2017·Biochimica et Biophysica Acta (BBA) - Molecular Cell Research

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.bbamcr.2017.06.009

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 212

  1. Brinckerhoff, 2002, Matrix metalloproteinases: a tail of a frog that became a prince, Nat. Rev. Mol. Cell Biol., 3, 207, 10.1038/nrm763 · DOI · Paper page
  2. Solomonov, 2016, Distinct biological events generated by ECM proteolysis by two homologous collagenases, Proc. Natl. Acad. Sci. U. S. A., 113, 10884, 10.1073/pnas.1519676113 · DOI
  3. Bode, 1993, Astacins, serralysins, snake venom and matrix metalloproteinases exhibit identical zinc-binding environments (HEXXHXXGXXH and Met-turn) and topologies and should be grouped into a common family, the ‘metzincins’, FEBS Lett., 331, 134, 10.1016/0014-5793(93)80312-I · DOI · Paper page
  4. Gaffney, 2015, Multilevel regulation of matrix metalloproteinases in tissue homeostasis indicates their molecular specificity in vivo, Matrix Biol., 44-46, 191, 10.1016/j.matbio.2015.01.012 · DOI
  5. Wong, 2015, The functional maturation of a disintegrin and metalloproteinase (ADAM) 9, 10, and 17 requires processing at a newly identified proprotein convertase (PC) cleavage site, J. Biol. Chem., 290, 12135, 10.1074/jbc.M114.624072 · DOI
  6. Nagase, 2006, Structure and function of matrix metalloproteinases and TIMPs, Cardiovasc. Res., 69, 562, 10.1016/j.cardiores.2005.12.002 · DOI · Paper page
  7. Murphy, 1994, Regulation of matrix metalloproteinase activity, Ann. N. Y. Acad. Sci., 732, 31, 10.1111/j.1749-6632.1994.tb24722.x · DOI · Paper page
  8. Mignatti, 1996, Plasminogen activators and matrix metalloproteinases in angiogenesis, Enzyme Protein, 49, 117, 10.1159/000468621 · DOI · Paper page
  9. Okamoto, 2001, Activation of matrix metalloproteinases by peroxynitrite-induced protein S-glutathiolation via disulfide S-oxide formation, J. Biol. Chem., 276, 29596, 10.1074/jbc.M102417200 · DOI · Paper page
  10. Fu, 2008, Activation and silencing of matrix metalloproteinases, Semin. Cell Dev. Biol., 19, 2, 10.1016/j.semcdb.2007.06.005 · DOI
  11. Martin, 2007, The other side of MMPs: protective roles in tumor progression, Cancer Metastasis Rev., 26, 717, 10.1007/s10555-007-9089-4 · DOI · Paper page
  12. Gialeli, 2011, Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting, FEBS J., 278, 16, 10.1111/j.1742-4658.2010.07919.x · DOI · Paper page
  13. Fingleton, 2008, MMPs as therapeutic targets—still a viable option?, Semin. Cell Dev. Biol., 19, 61, 10.1016/j.semcdb.2007.06.006 · DOI · Paper page
  14. Taraboletti, 1995, Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases, J. Natl. Cancer Inst., 87, 293, 10.1093/jnci/87.4.293 · DOI · Paper page
  15. Wada, 2003, Reduced angiogenesis in peritoneal dissemination of gastric cancer through gelatinase inhibition, Clin. Exp. Metastasis, 20, 431, 10.1023/A:1025453500148 · DOI
  16. Westwood, 2009, Characterization of fibrodysplasia in the dog following inhibition of metalloproteinases, Toxicol. Pathol., 37, 860, 10.1177/0192623309347909 · DOI
  17. Marshall, 2015, Selective allosteric inhibition of MMP9 is efficacious in preclinical models of ulcerative colitis and colorectal cancer, PLoS One, 10, 10.1371/journal.pone.0127063 · DOI · Paper page
  18. De Meijer, 2010, Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice, PLoS One, 5, 10.1371/journal.pone.0011256 · DOI
  19. Gaublomme, 2014, Matrix metalloproteinase 2 and membrane type 1 matrix metalloproteinase co-regulate axonal outgrowth of mouse retinal ganglion cells, J. Neurochem., 129, 966, 10.1111/jnc.12703 · DOI
  20. Bode, 2003, Structural basis of matrix metalloproteinase function, Biochem. Soc. Symp., 1
  21. Huang, 1996, Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli, FEBS Lett., 384, 155, 10.1016/0014-5793(96)00304-3 · DOI
  22. Murphy, 1991, The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity, Biochemistry, 30, 8097, 10.1021/bi00247a001 · DOI · Paper page
  23. de Bruyn, 2016, The molecular biology of matrix metalloproteinases and tissue inhibitors of metalloproteinases in inflammatory bowel diseases, Crit. Rev. Biochem. Mol. Biol., 51, 295, 10.1080/10409238.2016.1199535 · DOI
  24. O'Sullivan, 2015, Matrix metalloproteinases in inflammatory bowel disease: an update, Mediat. Inflamm., 964131, 10.1155/2015/964131 · DOI · Paper page
  25. Ricard-Blum, 2016, Matricryptins network with matricellular receptors at the surface of endothelial and tumor cells, Front. Pharmacol., 7, 11, 10.3389/fphar.2016.00011 · DOI
  26. Liu, 2001, Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth, Cancer Res., 61, 1022
  27. Weathington, 2006, A novel peptide CXCR ligand derived from extracellular matrix degradation during airway inflammation, Nat. Med., 12, 317, 10.1038/nm1361 · DOI · Paper page
  28. Feng, 2015, Collagen-derived N-acetylated proline-glycine-proline in intervertebral discs modulates CXCR1/2 expression and activation in cartilage endplate stem cells to induce migration and differentiation toward a pro-inflammatory phenotype, Stem Cells, 33, 3558, 10.1002/stem.2200 · DOI
  29. Hill, 2016, N-acetyl proline-glycine-proline: implications for neurological disorders., Neural Regen. Res., 11, 898, 10.4103/1673-5374.184478 · DOI
  30. Feng, 2017, The matrikine N-acetylated proline-glycine-proline induces premature senescence of nucleus pulposus cells via CXCR1-dependent ROS accumulation and DNA damage and reinforces the destructive effect of these cells on homeostasis of intervertebral discs, Biochim. Biophys. Acta (BBA) - Mol. Basis Dis., 1863, 220, 10.1016/j.bbadis.2016.10.011 · DOI
  31. Heinz, 2010, Degradation of tropoelastin by matrix metalloproteinases—cleavage site specificities and release of matrikines, FEBS J., 277, 1939, 10.1111/j.1742-4658.2010.07616.x · DOI
  32. Asundi, 2003, Matrix metalloproteinase-dependent shedding of syndecan-3, a transmembrane heparan sulfate proteoglycan, in Schwann cells, J. Neurosci. Res., 73, 593, 10.1002/jnr.10699 · doi:10.1002/jnr.10699
  33. Choi, 2015, Proteoglycans in health and disease: the multiple roles of syndecan shedding; the matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells, Oncotarget, 6, 3874, 10.18632/oncotarget.2885 · doi:10.18632/oncotarget.2885
  34. Arolas, 2012, Structural basis for the sheddase function of human meprin β metalloproteinase at the plasma membrane, Proc. Natl. Acad. Sci., 109, 16131, 10.1073/pnas.1211076109 · DOI
  35. Choi, 2010, The matrix metalloproteinase-7 regulates the extracellular shedding of syndecan-2 from colon cancer cells, Biochem. Biophys. Res. Commun., 417, 1260, 10.1016/j.bbrc.2011.12.120 · DOI
  36. Kwon, 2014, Interleukin-1α promotes extracellular shedding of syndecan-2 via induction of matrix metalloproteinase-7 expression, Biochem. Biophys. Res. Commun., 446, 487, 10.1016/j.bbrc.2014.02.142 · doi:10.1016/j.bbrc.2014.02.142
  37. Fears, 2006, Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells, J. Biol. Chem., 281, 14533, 10.1074/jbc.C600075200 · DOI
  38. Gaggar, 2008, A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic, J. Immunol., 180, 5662, 10.4049/jimmunol.180.8.5662 · DOI · Paper page
  39. Rebustini, 2009, Inflammation MT2-MMP-dependent release of collagen IV NC1 domains regulates submandibular gland branching morphogenesis, Dev. Cell, 17, 482, 10.1016/j.devcel.2009.07.016 · DOI
  40. Lindsey, 2015, A novel collagen matricryptin reduces left ventricular dilation post-myocardial infarction by promoting scar formation and angiogenesis., J. Am. Coll. Cardiol., 66, 1364, 10.1016/j.jacc.2015.07.035 · DOI · Paper page
  41. Xu, 2001, Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo, J. Cell Biol., 154, 1069, 10.1083/jcb.200103111 · DOI · Paper page
  42. Koshikawa, 2000, Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5, J. Cell Biol., 148, 615, 10.1083/jcb.148.3.615 · DOI · Paper page
  43. Pirilä, 2003, Matrix metalloproteinases process the laminin-5 gamma 2-chain and regulate epithelial cell migration, Biochem. Biophys. Res. Commun., 303, 1012, 10.1016/S0006-291X(03)00452-2 · DOI
  44. Mañes, 1997, Identification of insulin-like growth factor-binding protein-1 as a potential physiological substrate for human stromelysin-3, J. Biol. Chem., 272, 25706, 10.1074/jbc.272.41.25706 · DOI · Paper page
  45. Miyamoto, 2004, Matrix metalloproteinase-7 facilitates insulin-like growth factor bioavailability through its proteinase activity on insulin-like growth factor binding protein 3, Cancer Res., 64, 665, 10.1158/0008-5472.CAN-03-1916 · DOI
  46. Fowlkes, 1994, Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures, J. Biol. Chem., 269, 10.1016/S0021-9258(18)47310-3 · DOI · Paper page
  47. Rajah, 1999, Elevated levels of the IGF-binding protein protease MMP-1 in asthmatic airway smooth muscle, Am. J. Respir. Cell Mol. Biol., 20, 199, 10.1165/ajrcmb.20.2.3148 · doi:10.1165/ajrcmb.20.2.3148
  48. Fowlkes, 1999, MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth, Ann. N. Y. Acad. Sci., 878, 696, 10.1111/j.1749-6632.1999.tb07765.x · DOI
  49. Coppock, 2004, Matrix metalloprotease-3 and -9 proteolyze insulin-like growth factor-binding protein-1, Biol. Reprod., 71, 438, 10.1095/biolreprod.103.023101 · DOI
  50. Imai, 1997, Protease-resistant form of insulin-like growth factor-binding protein 5 is an inhibitor of insulin-like growth factor-I actions on porcine smooth muscle cells in culture, J. Clin. Invest., 100, 2596, 10.1172/JCI119803 · DOI
  51. Zhang, 2004, Dual regulation of MMP-2 expression by the type 1 insulin-like growth factor receptor the phosphatidylinositol 3-kinase/Akt and Raf/ERK pathways transmit opposing signals, J. Biol. Chem., 279, 19683, 10.1074/jbc.M313145200 · DOI
  52. Chattopadhyay, 2009, MMP-9 controls Schwann cell proliferation and phenotypic remodeling via IGF-1 and ErbB receptor-mediated activation of MEK/ERK pathway, Glia, 57, 1316, 10.1002/glia.20851 · DOI
  53. Samani, 2009, The role of the IGF system in cancer growth and metastasis: overview and recent insights, Endocr. Rev., 28, 20, 10.1210/er.2006-0001 · DOI · Paper page
  54. Yu, 2000, Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis, Genes Dev., 14, 163, 10.1101/gad.14.2.163 · DOI · Paper page
  55. Dangelo, 2001, Activation of transforming growth factor beta in chondrocytes undergoing endochondral ossification, J. Bone Miner. Res., 16, 2339, 10.1359/jbmr.2001.16.12.2339 · DOI
  56. Mu, 2002, The integrin alpha(v)beta8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-beta1, J. Cell Biol., 157, 493, 10.1083/jcb.200109100 · DOI · Paper page
  57. Khan, 2016, The role of proteases in transforming growth factor-β activation, Cell Tissue Res., 365, 657, 10.1007/s00441-016-2474-y · DOI
  58. Velasco-Loyden, 2004, The shedding of betaglycan is regulated by pervanadate and mediated by membrane type matrix metalloprotease-1, J. Biol. Chem., 279, 7721, 10.1074/jbc.M306499200 · DOI
  59. Finnson, 2013, Dynamics of transforming growth factor beta signaling in wound healing and scarring, Adv. Wound Care, 2, 195, 10.1089/wound.2013.0429 · DOI · Paper page
  60. Colnot, 2003, Altered fracture repair in the absence of MMP9, Development, 130, 4123, 10.1242/dev.00559 · DOI · Paper page
  61. Lee, 2005, Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors, J. Cell Biol., 169, 681, 10.1083/jcb.200409115 · DOI · Paper page
  62. Ito, 2007, The VEGF angiogenic switch of fibroblasts is regulated by MMP-7 from cancer cells, Oncogene, 26, 7194, 10.1038/sj.onc.1210535 · DOI
  63. Munaut, 2003, Vascular endothelial growth factor expression correlates with matrix metalloproteinases MT1-MMP, MMP-2 and MMP-9 in human glioblastomas, Int. J. Cancer, 106, 848, 10.1002/ijc.11313 · DOI · Paper page
  64. Eisenach, 2010, MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src, J. Cell Sci., 123, 4182, 10.1242/jcs.062711 · DOI
  65. Dean, 2007, Mol. Cell. Biol., 27, 8454, 10.1128/MCB.00821-07 · DOI · Paper page
  66. Héroult, 2004, Heparin affin regulatory peptide binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis, Oncogene, 23, 1745, 10.1038/sj.onc.1206879 · DOI
  67. Hashimoto, 2002, Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165, J. Biol. Chem., 277, 36288, 10.1074/jbc.M201674200 · DOI · Paper page
  68. Ito, 1996, Degradation of interleukin 1, J. Biol. Chem., 271, 14657, 10.1074/jbc.271.25.14657 · DOI · Paper page
  69. Schönbeck, 1998, Generation of biologically active IL-1 beta bymatrix metalloproteinases: a novel caspase-1-independent pathway of IL-1 betaprocessing, J. Immunol., 161, 3340, 10.4049/jimmunol.161.7.3340 · DOI · Paper page
  70. Tester, 2007, LPS responsiveness and neutrophil chemotaxis in vivo require PMN MMP-8 activity, PLoS One, 2, 10.1371/journal.pone.0000312 · DOI · Paper page
  71. Le Quément, 2008, MMP-12 induces IL-8/CXCL8 secretion through EGFR and ERK1/2 activation in epithelial cells, Am. J. Phys. Lung Cell. Mol. Phys., 294, L1076
  72. Van den Steen, 2000, Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO- alpha and leaves RANTES and MCP-2 intact, Blood, 96, 2673, 10.1182/blood.V96.8.2673 · DOI · Paper page
  73. Nelissen, 2003, Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy, Brain, 126, 1371, 10.1093/brain/awg129 · DOI
  74. Westermann, 2011, Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy, Circulation, 124, 2082, 10.1161/CIRCULATIONAHA.111.035964 · DOI
  75. Vassalli, 1992, The pathophysiology of tumor necrosis factors, Annu. Rev. Immunol., 10, 411, 10.1146/annurev.iy.10.040192.002211 · doi:10.1146/annurev.iy.10.040192.002211 · Paper page
  76. Gearing, 1994, Processing of tumour necrosis factor-alpha precursor by metalloproteinases, Nature, 370, 555, 10.1038/370555a0 · DOI · Paper page
  77. Chandler, 1996, Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alfa fusion protein, Biochem. Biophys. Res. Commun., 228, 421, 10.1006/bbrc.1996.1677 · DOI · Paper page
  78. d'Ortho, 1997, Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases, Eur. J. Biochem., 250, 751, 10.1111/j.1432-1033.1997.00751.x · DOI · Paper page
  79. Tam, 2004, Membrane protease proteomics: isotope-coded affinity tag MS identification of undescribed MT1-matrix metalloproteinase substrates, Proc. Natl. Acad. Sci. U. S. A., 101, 6917, 10.1073/pnas.0305862101 · DOI · Paper page
  80. Vandenbroucke, 2013, Matrix metalloproteinase 13 modulates intestinal epithelial barrier integrity in inflammatory diseases by activating TNF, EMBO Mol. Med., 5, 1000, 10.1002/emmm.201202100 · DOI
  81. English, 2000, Membrane type 4 matrix metalloproteinase (MMP17) has tumor necrosis factor-alpha convertase activity but does not activate pro-MMP2, J. Biol. Chem., 275, 14046, 10.1074/jbc.275.19.14046 · DOI · Paper page
  82. Jin, 2008, Degradation of BM SDF-1 by MMP-9: the role in G-CSF-induced hematopoietic stem/progenitor cell mobilization, Bone Marrow Transplant., 42, 581, 10.1038/bmt.2008.222 · DOI
  83. Abdul-Muneer, 2017, Traumatic brain injury induced matrix metalloproteinase2 cleaves CXCL12α (stromal cell derived factor 1α) and causes neurodegeneration, Brain Behav. Immun., 59, 190, 10.1016/j.bbi.2016.09.002 · DOI
  84. McGuire, 2003, Matrilysin (matrix metalloproteinase-7) mediates E-cadherin ectodomain shedding in injured lung epithelium, Am. J. Pathol., 162, 1831, 10.1016/S0002-9440(10)64318-0 · DOI · Paper page
  85. Noë, 2001, Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1, J. Cell Sci., 114, 111, 10.1242/jcs.114.1.111 · DOI · Paper page
  86. Lochter, 1997, Matrix metalloproteinase stromelysin-1 triggers a cascade of molecular alterations that leads to stable epithelial-to-mesenchymal conversion and a premalignant phenotype in mammary epithelial cells, J. Cell Biol., 139, 1861, 10.1083/jcb.139.7.1861 · DOI · Paper page
  87. Cavallaro, 2004, Cell adhesion and signaling by cadherins and Ig-CAMs in cancer, Nat. Rev. Cancer, 4, 118, 10.1038/nrc1276 · DOI · Paper page
  88. Nawrocki-Raby, 2003, Upregulation of MMPs by soluble E-cadherin in human lung tumor cells, Int. J. Cancer, 105, 790, 10.1002/ijc.11168 · DOI
  89. Deryugina, 2002, Processing of integrin alpha(v) subunit by membrane type 1 matrix metalloproteinase stimulates migration of breast carcinoma cells on vitronectin and enhances tyrosine phosphorylation of focal adhesion kinase, J. Biol. Chem., 277, 9749, 10.1074/jbc.M110269200 · DOI · Paper page
  90. Abdel-Ghany, 2001, The breast cancer beta 4 integrin and endothelial human CLCA2 mediate lung metastasis, J. Biol. Chem., 276, 25438, 10.1074/jbc.M100478200 · DOI
  91. Kajita, 2001, Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration, J. Cell Biol., 153, 893, 10.1083/jcb.153.5.893 · DOI · Paper page
  92. Marrero-Diaz, 2009, Polarized MT1-MMP-CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion, Cell Motil. Cytoskeleton, 66, 48, 10.1002/cm.20325 · DOI
  93. Chetty, 2012, MMP-9 induces CD44 cleavage and CD44 mediated cell migration in glioblastoma xenograft cells, Cell. Signal., 24, 549, 10.1016/j.cellsig.2011.10.008 · DOI
  94. Iyer, 2015, Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution, Int. J. Cardiol., 185, 10.1016/j.ijcard.2015.03.054 · DOI
  95. Jiang, 2015, CD44 regulates pancreatic cancer invasion through MT1-MMP, Mol. Cancer Res., 13, 9, 10.1158/1541-7786.MCR-14-0076 · DOI
  96. Yu, 2002, CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling, Genes Dev., 16, 307, 10.1101/gad.925702 · DOI · Paper page
  97. Levi, 1996, Matrix metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1, Proc. Natl. Acad. Sci. U. S. A., 93, 7069, 10.1073/pnas.93.14.7069 · DOI · Paper page
  98. Talmi-Frank, 2016, Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality., Cell Host Microbe, 20, 458, 10.1016/j.chom.2016.09.005 · DOI
  99. Houghton, 2009, Macrophage elastase kills bacteria within murine macrophages, Nature, 460, 637, 10.1038/nature08181 · DOI · Paper page
  100. Elkington, 2011, Matrix metalloproteinases in tuberculosis, Eur. Respir. J., 38, 456, 10.1183/09031936.00015411 · DOI
  101. Sathyamoorthy, 2015, Membrane type 1 matrix metalloproteinase regulates monocyte migration and collagen destruction in tuberculosis, J. Immunol., 195, 882, 10.4049/jimmunol.1403110 · DOI
  102. Rosenberg, 2002, Matrix metalloproteinases in neuroinflammation, Glia, 39, 279, 10.1002/glia.10108 · DOI · Paper page
  103. Wang, 2014, Matrix metalloproteinases and their multiple roles in Alzheimer's disease, Biomed. Res. Int., 2014, 908636
  104. Lukaszewicz-Zajac, 2014, Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in amyotrophic lateral sclerosis (ALS), J. Neural. Transm. (Vienna), 121, 1387, 10.1007/s00702-014-1205-3 · DOI
  105. Rosenberg, 2002, Matrix metalloproteinases and neuroinflammation in multiple sclerosis, Neuroscientist, 8, 586, 10.1177/1073858402238517 · DOI
  106. Noble, 2002, Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events, J. Neurosci., 22, 7526, 10.1523/JNEUROSCI.22-17-07526.2002 · DOI · Paper page
  107. Zhao, 2006, Role of matrix metalloproteinases in delayed cortical responses after stroke, Nat. Med., 12, 441, 10.1038/nm1387 · DOI · Paper page
  108. Lakhan, 2012, Matrix metalloproteinases in neuropathic pain and migraine: friends, enemies, and therapeutic targets, Pain Res. Treat., 2012, 952906
  109. Ahmed, 2011, Novel targets for spinal cord injury related neuropathic pain, Ann. Neurosci., 18, 162, 10.5214/ans.0972.7531.1118413 · DOI
  110. Ji, 2009, Matrix metalloprotease regulation of neuropathic pain, Trends Pharmacol. Sci., 30, 336, 10.1016/j.tips.2009.04.002 · DOI · Paper page
  111. Fields, 2015, New strategies for targeting matrix metalloproteinases, Matrix Biol., 44-46, 239, 10.1016/j.matbio.2015.01.002 · DOI · Paper page
  112. Kleifeld, 2001, X-ray absorption studies of human matrix metalloproteinase-2 (MMP-2) bound to a highly selective mechanism-based inhibitor. Comparison with the latent and active forms of the enzyme, J. Biol. Chem., 276, 17125, 10.1074/jbc.M011604200 · DOI
  113. Pirard, 2007, Insight into the structural determinants for selective inhibition of matrix metalloproteinases, Drug Discov. Today, 12, 640, 10.1016/j.drudis.2007.06.003 · DOI
  114. Overall, 2006, Towards third generation matrix metalloproteinase inhibitors for cancer therapy, Br. J. Cancer, 94, 941, 10.1038/sj.bjc.6603043 · DOI · Paper page
  115. Devel, 2006, Development of selective inhibitors and substrate of matrix metalloproteinase-12, J. Biol. Chem., 281, 11152, 10.1074/jbc.M600222200 · DOI
  116. Devel, 2010, Third generation of matrix metalloprotease inhibitors: gain in selectivity by targeting the depth of the S1′ cavity, Biochimie, 92, 1501, 10.1016/j.biochi.2010.07.017 · DOI
  117. Rouanet-Mehouas, 2017, Zinc-metalloproteinase inhibitors: evaluation of the complex role played by the zinc-binding group on potency and selectivity, J. Med. Chem., 60, 403, 10.1021/acs.jmedchem.6b01420 · DOI
  118. Lopez-Otin, 2009, Protective roles of matrix metalloproteinases: from mouse models to human cancer, Cell Cycle (Georgetown, Tex), 8, 3657, 10.4161/cc.8.22.9956 · DOI
  119. Overall, 2006, Tumour microenvironment — opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy, Nat. Rev. Cancer, 6, 227, 10.1038/nrc1821 · DOI · Paper page
  120. Sela-Passwell, 2010, Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?, Biochim. Biophys. Acta, 1803, 29, 10.1016/j.bbamcr.2009.04.010 · DOI
  121. Sela-Passwell, 2010, Structural and functional bases for allosteric control of MMP activities: can it pave the path for selective inhibition?, BBA Mol. Cell Res., 1803, 29
  122. Bhowmick, 2015, Matrix metalloproteinase inhibition by heterotrimeric triple-helical peptide transition state analogues, Chembiochem, 16, 1084, 10.1002/cbic.201402716 · DOI
  123. Deu, 2012, New approaches for dissecting protease functions to improve probe development and drug discovery, Nat. Struct. Mol. Biol., 19, 9, 10.1038/nsmb.2203 · DOI · Paper page
  124. Turk, 2006, Targeting proteases: successes, failures and future prospects, Nat. Rev. Drug Discov., 5, 785, 10.1038/nrd2092 · DOI · Paper page
  125. Udi, 2013, Unraveling hidden regulatory sites in structurally homologous metalloproteases, J. Mol. Biol., 425, 2330, 10.1016/j.jmb.2013.04.009 · DOI
  126. Laskowski, 2009, The structural basis of allosteric regulation in proteins, FEBS Lett., 583, 1692, 10.1016/j.febslet.2009.03.019 · DOI · Paper page
  127. Wu, 2007, Structural insight into distinct mechanisms of protease inhibition by antibodies, Proc. Natl. Acad. Sci. U. S. A., 104, 19784, 10.1073/pnas.0708251104 · DOI
  128. Sela-Passwell, 2012, Antibodies targeting the catalytic zinc complex of activated matrix metalloproteinases show therapeutic potential, Nat. Med., 18, 143, 10.1038/nm.2582 · DOI
  129. Chothia, 1987, Canonical structures for the hypervariable regions of immunoglobulins, J. Mol. Biol., 196, 901, 10.1016/0022-2836(87)90412-8 · DOI · Paper page
  130. MacCallum, 1996, Antibody-antigen interactions: contact analysis and binding site topography, J. Mol. Biol., 262, 732, 10.1006/jmbi.1996.0548 · DOI · Paper page
  131. Garg, 2009, Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis, Am. J. Physiol. Gastrointest. Liver, 296, G175, 10.1152/ajpgi.90454.2008 · DOI
  132. Paemen, 1995, Monoclonal antibodies specific for natural human neutrophil gelatinase B used for affinity purification, quantitation by two-site ELISA and inhibition of enzymatic activity, Eur. J. Biochem., 234, 759, 10.1111/j.1432-1033.1995.759_a.x · DOI
  133. Hu, 2004, Inhibitors of gelatinase B/matrix metalloproteinase-9 activity comparison of a peptidomimetic and polyhistidine with single-chain derivatives of a neutralizing monoclonal antibody, Biochem. Pharmacol., 67, 1001, 10.1016/j.bcp.2003.10.030 · DOI
  134. Martens, 2007, A monoclonal antibody inhibits gelatinase B/MMP-9 by selective binding to part of the catalytic domain and not to the fibronectin or zinc binding domains, Biochim. Biophys. Acta, 1770, 178, 10.1016/j.bbagen.2006.10.012 · DOI
  135. Pruijt, 1999, Prevention of interleukin-8-induced mobilization of hematopoietic progenitor cells in rhesus monkeys by inhibitory antibodies against the metalloproteinase gelatinase B (MMP-9), Proc. Natl. Acad. Sci. U. S. A., 96, 10863, 10.1073/pnas.96.19.10863 · DOI · Paper page
  136. Galvez, 2001, Membrane type 1-matrix metalloproteinase is activated during migration of human endothelial cells and modulates endothelial motility and matrix remodeling, J. Biol. Chem., 276, 37491, 10.1074/jbc.M104094200 · DOI · Paper page
  137. Talmi-Frank, 2016, Extracellular matrix proteolysis by MT1-MMP contributes to influenza-related tissue damage and mortality, Cell Host Microbe, 20, 458, 10.1016/j.chom.2016.09.005 · DOI
  138. Udi, 2015, Inhibition mechanism of membrane metalloprotease by an exosite-swiveling conformational antibody, Structure, 23, 104, 10.1016/j.str.2014.10.012 · DOI
  139. Ingvarsen, 2013, Targeting a single function of the multifunctional matrix metalloprotease MT1-MMP: impact on lymphangiogenesis, J. Biol. Chem., 288, 10195, 10.1074/jbc.M112.447169 · DOI
  140. Shiryaev, 2013, A monoclonal antibody interferes with TIMP-2 binding and incapacitates the MMP-2-activating function of multifunctional, pro-tumorigenic MMP-14/MT1-MMP, Oncogene, 2
  141. Butler, 1998, The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. A kinetic study, J. Biol. Chem., 273, 871, 10.1074/jbc.273.2.871 · DOI · Paper page
  142. Knauper, 1996, Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme, J. Biol. Chem., 271, 17124
  143. Strongin, 1995, Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease, J. Biol. Chem., 270, 5331, 10.1074/jbc.270.10.5331 · DOI · Paper page
  144. Detry, 2012, Matrix metalloproteinase-2 governs lymphatic vessel formation as an interstitial collagenase, Blood, 119, 5048, 10.1182/blood-2011-12-400267 · DOI
  145. Nam, 2016, Active-site MMP-selective antibody inhibitors discovered from convex paratope synthetic libraries, Proc. Natl. Acad. Sci. U. S. A., 113, 14970, 10.1073/pnas.1609375114 · DOI
  146. Sircar, 2011, Analysis and modeling of the variable region of camelid single-domain antibodies, J. Immunol., 186, 6357, 10.4049/jimmunol.1100116 · DOI · Paper page
  147. Moss, 2007, The ADAM10 prodomain is a specific inhibitor of ADAM10 proteolytic activity and inhibits cellular shedding events, J. Biol. Chem., 282, 35712, 10.1074/jbc.M703231200 · DOI
  148. Wong, 2016, Harnessing the natural inhibitory domain to control TNFalpha Converting Enzyme (TACE) activity in vivo, Sci Rep, 6, 35598, 10.1038/srep35598 · DOI
  149. Moss, 2008, Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis, Nat. Clin. Pract. Rheumatol., 4, 300, 10.1038/ncprheum0797 · DOI · Paper page
  150. Feldmann, 1996, Role of cytokines in rheumatoid arthritis, Annu. Rev. Immunol., 14, 397, 10.1146/annurev.immunol.14.1.397 · DOI · Paper page
  151. Papadakis, 2000, Role of cytokines in the pathogenesis of inflammatory bowel disease, Annu. Rev. Med., 51, 289, 10.1146/annurev.med.51.1.289 · DOI · Paper page
  152. Kefaloyianni, 2016, ADAM17 substrate release in proximal tubule drives kidney fibrosis, JCI Insight, 1, 10.1172/jci.insight.87023 · DOI
  153. Gur-Cohen, 2015, PAR1 signaling regulates the retention and recruitment of EPCR-expressing bone marrow hematopoietic stem cells, Nat. Med., 21, 1307, 10.1038/nm.3960 · DOI
  154. Said, 2014, The role of matrix metalloproteinases in colorectal cancer, Cancer, 6, 366, 10.3390/cancers6010366 · DOI · Paper page
  155. Ding, 2011, Endothelial-derived angiocrine signals induce and sustain regenerative lung alveolarization, Cell, 147, 539, 10.1016/j.cell.2011.10.003 · DOI · Paper page
  156. Antoni, 2013, Crystallization of bi-functional ligand protein complexes, J. Struct. Biol., 182, 246, 10.1016/j.jsb.2013.03.015 · DOI
  157. Morgunova, 1999, Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed, Science, 284, 1667, 10.1126/science.284.5420.1667 · DOI · Paper page
  158. Lee, 2003, Unveiling the surface epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase, J. Biol. Chem., 278, 40224, 10.1074/jbc.M305678200 · DOI
  159. Chao, 2006, Isolating and engineering human antibodies using yeast surface display, Nat. Protoc., 1, 755, 10.1038/nprot.2006.94 · DOI · Paper page
  160. Whitehead, 2012, Optimization of affinity, specificity and function of designed influenza inhibitors using deep sequencing, Nat. Biotechnol., 30, 543, 10.1038/nbt.2214 · DOI · Paper page
  161. Levin, 2013, Employing directed evolution for the functional analysis of multi-specific proteins, Bioorg. Med. Chem., 21, 3511, 10.1016/j.bmc.2013.04.052 · DOI
  162. Aharoni, 2004, Directed evolution of recombinant serum paraoxonase (PON) variants, Discov. Med., 4, 120
  163. Aharoni, 2005, High-throughput screens and selections of enzyme-encoding genes, Curr. Opin. Chem. Biol., 9, 210, 10.1016/j.cbpa.2005.02.002 · DOI · Paper page
  164. Lutz, 2010, Beyond directed evolution—semi-rational protein engineering and design, Curr. Opin. Biotechnol., 21, 734, 10.1016/j.copbio.2010.08.011 · DOI · Paper page
  165. Kintzing, 2016, Emerging strategies for developing next-generation protein therapeutics for cancer treatment, Trends Pharmacol. Sci., 10.1016/j.tips.2016.10.005 · DOI · Paper page
  166. Bahudhanapati, 2011, Phage display of tissue inhibitor of metalloproteinases-2 (TIMP-2) identification of selective inhibitors of collagenase-1 (metalloproteinase 1 (MMP-1)), J. Biol. Chem., 286, 31761, 10.1074/jbc.M111.253328 · DOI
  167. Sharabi, 2014, Affinity-and specificity-enhancing mutations are frequent in multispecific interactions between TIMP2 and MMPs, PLoS One, 9, 10.1371/journal.pone.0093712 · DOI
  168. Rabinovich, 2016, Identifying residues that determine SCF molecular-level interactions through a combination of experimental and in silico analyses, J. Mol. Biol.
  169. Boder, 2000, Yeast surface display for directed evolution of protein expression, affinity, and stability, Methods Enzymol., 328, 430, 10.1016/S0076-6879(00)28410-3 · DOI · Paper page
  170. Roodveldt, 2005, Directed evolution of proteins for heterologous expression and stability, Curr. Opin. Struct. Biol., 15, 50, 10.1016/j.sbi.2005.01.001 · DOI
  171. Amar, 2012, The transition of human estrogen sulfotransferase from generalist to specialist using directed enzyme evolution, J. Mol. Biol., 416, 21, 10.1016/j.jmb.2011.12.013 · DOI
  172. Xia, 2002, Directed evolution of novel polymerase activities: mutation of a DNA polymerase into an efficient RNA polymerase, Proc. Natl. Acad. Sci., 99, 6597, 10.1073/pnas.102577799 · DOI
  173. Cathcart, 2015, Targeting matrix metalloproteinases in cancer: bringing new life to old ideas, Genes Dis., 2, 26, 10.1016/j.gendis.2014.12.002 · DOI · Paper page
  174. Jabaiah, 2011, Directed evolution of protease beacons that enable sensitive detection of endogenous MT1-MMP activity in tumor cell lines, Chem. Biol., 18, 392, 10.1016/j.chembiol.2010.12.017 · DOI
  175. Miller, 2011, Proteolytic Activity Matrix Analysis (PrAMA) for simultaneous determination of multiple protease activities, Integr. Biol., 3, 422, 10.1039/C0IB00083C · DOI
  176. Gura, 2002, Therapeutic antibodies: magic bullets hit the target, Nature, 417, 584, 10.1038/417584a · DOI
  177. Sgro, 1995, Side-effects of a monoclonal antibody, muromonab CD3/orthoclone OKT3: bibliographic review, Toxicology, 105, 23, 10.1016/0300-483X(95)03123-W · DOI · Paper page
  178. Kettleborough, 1991, Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation, Protein Eng., 4, 773, 10.1093/protein/4.7.773 · DOI · Paper page
  179. Holliger, 2005, Engineered antibody fragments and the rise of single domains, Nat. Biotechnol., 23, 1126, 10.1038/nbt1142 · DOI · Paper page
  180. Schrama, 2006, Antibody targeted drugs as cancer therapeutics, Nat. Rev. Drug Discov., 5, 147, 10.1038/nrd1957 · DOI · Paper page
  181. Pfaffen, 2010, Isolation and characterization of human monoclonal antibodies specific to MMP-1A, MMP-2 and MMP-3, Exp. Cell Res., 316, 836, 10.1016/j.yexcr.2009.11.004 · DOI
  182. Botkjaer, 2016, Development of a specific affinity-matured exosite inhibitor to MT1-MMP that efficiently inhibits tumor cell invasion in vitro and metastasis in vivo, Oncotarget, 7, 16773, 10.18632/oncotarget.7780 · DOI
  183. Remacle, 2016, Selective function-blocking monoclonal human antibody highlights the important role of membrane type-1 matrix metalloproteinase (MT1-MMP) in metastasis, Oncotarget
  184. Knight, 1992, A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases, FEBS Lett., 296, 263, 10.1016/0014-5793(92)80300-6 · DOI · Paper page
  185. Souriau, 2003, Recombinant antibodies for cancer diagnosis and therapy, Expert. Opin. Biol. Ther., 3, 305, 10.1517/14712598.3.2.305 · DOI
  186. Hoet, 2005, Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity, Nat. Biotechnol., 23, 344, 10.1038/nbt1067 · DOI · Paper page
  187. Devy, 2009, Selective inhibition of matrix metalloproteinase-14 blocks tumor growth, invasion, and angiogenesis, Cancer Res., 69, 1517, 10.1158/0008-5472.CAN-08-3255 · DOI · Paper page
  188. Schreuder, 1993, Targeting of a heterologous protein to the cell wall of Saccharomyces cerevisiae, Yeast, 9, 399, 10.1002/yea.320090410 · DOI · Paper page
  189. Boder, 1997, Yeast surface display for screening combinatorial polypeptide libraries, Nat. Biotechnol., 15, 553, 10.1038/nbt0697-553 · DOI · Paper page
  190. Esteban, 2004, Directed evolution of soluble single-chain human class II MHC molecules, J. Mol. Biol., 340, 81, 10.1016/j.jmb.2004.04.054 · DOI
  191. Jones, 2006, Engineering and characterization of a stabilized α1/α2 module of the class I major histocompatibility complex product Ld, J. Biol. Chem., 281, 25734, 10.1074/jbc.M604343200 · DOI
  192. Shusta, 1999, Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency, J. Mol. Biol., 292, 949, 10.1006/jmbi.1999.3130 · DOI · Paper page
  193. Kim, 2006, Directed evolution of the epidermal growth factor receptor extracellular domain for expression in yeast, Proteins Struct. Funct. Bioinf., 62, 1026, 10.1002/prot.20618 · doi:10.1002/prot.20618
  194. Rajpal, 2005, A general method for greatly improving the affinity of antibodies by using combinatorial libraries, Proc. Natl. Acad. Sci. U. S. A., 102, 8466, 10.1073/pnas.0503543102 · DOI
  195. Boder, 2000, Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity, Proc. Natl. Acad. Sci., 97, 10701, 10.1073/pnas.170297297 · DOI · Paper page
  196. Mehner, 2013, Engineering TIMP-1 for selective MMP inhibition and future use as a protein therapeutic, Cancer Res., 73, 5069, 10.1158/1538-7445.AM2013-5069 · doi:10.1158/1538-7445.am2013-5069
  197. Grossman, 2010, The intrinsic protein flexibility of endogenous protease inhibitor TIMP-1 controls its binding interface and affects its function, Biochemistry, 49, 6184, 10.1021/bi902141x · DOI · Paper page
  198. Meng, 1999, Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1′ residue of substrate, J. Biol. Chem., 274, 10184, 10.1074/jbc.274.15.10184 · DOI
  199. Nagase, 2002, Engineering of tissue inhibitor of metalloproteinases mutants as potential therapeutics, Arthritis Res. Ther., 4, 1
  200. Berger, 2011, The molecular basis for the broad substrate specificity of human sulfotransferase 1A1, PLoS One, 6, 10.1371/journal.pone.0026794 · DOI

200 of 212 shown

Cited by

See all 186

Metadata

Authors
Levin, M., Udi, Y., Solomonov, I., & Sagi, I.
Venue
Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
Publisher
Elsevier BV
Published
2017-11
Volume
1864
Issue
11
Pages
1927-1939
ISSN
0167-4889 (ISSN-L)
OpenAlex
W2659780310
Cited by
186
References
13
FWCI
6.47
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • European Research Council (DLV-695437)
  • Minerva Foundation (712592-01)
  • Israel Science Foundation (1226/13)
  • United States - Israel Binational Science Foundation (712506-01)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects. https://app.cochat.ai/papers/10.1016/j.bbamcr.2017.06.009
The paper
Levin, M., Udi, Y., Solomonov, I., & Sagi, I. (2017). Next generation matrix metalloproteinase inhibitors — Novel strategies bring new prospects. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. https://doi.org/10.1016/j.bbamcr.2017.06.009

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.